Latest News

TeVido BioDevices Receives Phase II SBIR Grant from National Science Foundation for Breast Reconstruction using 3D Bioprinting.

Award validates approach for novel treatments that provide benefit to breast cancer survivors.

Austin, TX (PRWEB) October 15, 2014

TeVido BioDevices, an early stage 3D bioprinting company creating natural human grafts for reconstructive procedures, announced today, Breast Reconstruction Awareness (BRA) Day, receipt of a Small Business Innovation Research (SBIR) Phase II Grant from the National Science Foundation (NSF) to fund further preclinical development of the company’s novel breast reconstruction program. The SBIR grant will enable TeVido to perform preclinical in vitro and in vivo studies for future regulatory filings supporting human clinical trials in patients undergoing breast reconstruction post-mastectomy.

Globally nearly 1.5 million women receive a diagnosis of breast cancer each year, and in the United States it is estimated that forty percent of the nearly 300,000 women diagnosed undergo mastectomy or full removal of the breast tissue as part of their cancer treatment regime. Approximately one-third of all mastectomy patients will undergo breast reconstruction, with the final step in the process involving the nipple areola complex (NAC). Unfortunately, results of currently available NAC reconstruction techniques are unpredictable. Studies highlight that patients with loss of the nipple and areola continue to experience psychological distress even long after breast mound reconstruction has taken place and recreation of the nipple-areola complex has a high correlation with overall patient satisfaction and acceptance of body image.

TeVido’s innovative solutions aim to address the challenges that post-mastectomy patients face by developing a proprietary bioprinting technology called Cellatier™, to build custom grafts for reconstructive procedures using 3D bioprinting. The initial research focuses on creating NAC grafts, where there is a high unmet need in reconstruction for breast cancer survivors. Longer term, TeVido intends to develop CellatierTM technology to address the unmet challenge in filling lumpectomy voids and breast contouring.

“We appreciate the continued NSF support of our mission to transform reconstructive options for survivors,” said Laura Bosworth CEO and Co-founder of TeVido. “Breast Cancer Awareness Month’s pink movement has been instrumental in driving early detection of breast cancer which has saved perhaps millions of lives. The SBIR grant program plays a vital role in assisting companies like ours to innovate the next frontier in reconstruction options for survivors aimed at improving their long term healing and quality of life. We are encouraged by the strides that are being made in early detection, and very pleased to have the opportunity to partner with NSF to achieve our vision of providing new hope to breast cancer survivors around the world.”    

“The NSF Small Business Innovation Research (SBIR) supports some of the most promising US start-up companies,” said Jesus Soriano, SBIR/STTR Program Director for Biomedical and Smart Health Technologies. “Companies like TeVido are vetted by NSF’s rigorous merit review process, which seeks early-stage companies developing transformational technologies with high potential for significant societal and commercial impact. For decades, NSF SBIR companies have been helping to stimulate the U.S. economy and to improve lives.”

About TeVido BioDevices

TeVido BioDevices is a privately-held biotechnology company using proprietary 3D bio-printing technology to build natural human grafts for reconstructive procedures. TeVido’s vision is to change the current approach to reconstructive surgery, starting by improving options and self-esteem for breast cancer survivors and expanding capability to other reconstructive indications that provide significant benefit to patients. TeVido’s technology and approach has been the focus of feature articles in CNN with Dr. Sanjay Gupta, Huffington Post Live, Al Jazeera TV as well as The Economist, Popular Science, The Guardian (UK), and several other publications. For more information visit

About the National Science Foundation

The National Science Foundation (NSF) is an independent federal agency that supports fundamental research and education across all fields of science and engineering. In fiscal year (FY) 2014, its budget is $7.2 billion. NSF funds reach all 50 states through grants to nearly 2,000 colleges, universities and other institutions. Each year, NSF receives about 50,000 competitive requests for funding, and makes about 11,500 new funding awards. NSF also awards about $593 million in professional and service contracts yearly.

For the original version on PRWeb visit:

Leave a comment

seks shop - izolasyon
basic theory test book basic theory test